Lung-Cancer Specific T Cell Dysfunction
Invention type: Technology
/
Case number: #23004
Methods for identifying patients susceptible to treatment with checkpoint inhibitors are provided herein. Also provided are reagents for analyzing T cell responses for understanding resistance to checkpoint inhibitor therapy and understanding therapeutics for overcoming that resistance. Therapeutic strategies, for instance, for treating cancer, are also provided.
Researchers
Departments: Department of Chemical Engineering, Department of Biology
Technology Areas: Drug Discovery and Research Tools: Cell Interrogation, Cell Lines & Organoids / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living
-
lung-cancer specific t cell dysfunction
United States of America | Pending
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.